DNA RNA and Cells
12 January 2015
Arrowhead Provides Update on IND for ARC-520 Phase 2b Study9 January 2015
Isarna Therapeutics Unveils New Selective TGF-beta Antagonist Program Targeting Multiple Indications in Ophthalmology7 January 2015
ProNAi Initiates Phase II Trial of PNT2258 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)6 January 2015
Cellular Biomedicine Group Initiates Patient Recruitment for Cartilage Damage Stem Cell Therapy Clinical Research Study5 January 2015
BrainStorm Announces Final Analysis of Phase 2a ALS Study Showing Nearly All Subjects Experienced Clinical Benefit from NurOwn5 January 2015
Lion Biotechnologies Submits Investigational New Drug Application to Conduct Phase 2 Study in Metastatic Melanoma5 January 2015
Sirnaomics and Partner Submit IND to CFDA for Its First Anti-fibrosis siRNA Therapeutic30 December 2014
OncoGenex to Regain Rights to Custirsen from Teva29 December 2014
Athersys Finishes Enrollment of Phase 2 Study of MultiStem(R) Cell Therapy for Ischemic Stroke24 December 2014
Novastem Treats First Patient Using Stemedica’s Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke23 December 2014
VBL Therapeutics Announces Positive Phase 2a Data for VB-111 in Recurrent Thyroid Cancer20 December 2014
First stem-cell therapy recommended for approval in EU19 December 2014
OncoGenex Announces Results from the Phase 2 Borealis-1(TM) Trial of Apatorsen in the Treatment of Metastatic Bladder Cancer17 December 2014
Cell Therapy Catapult: First Patient in Trial Given New T-cell Therapy for Leukaemia16 December 2014
Isis Pharmaceuticals Initiates Phase 1/2 Study of ISIS-DMPK Rx in Patients With Myotonic Dystrophy Type 116 December 2014
Bone Therapeutics Confirms Safety in ALLOB® Phase I/IIa Trial for Delayed-Union Fractures15 December 2014
Arrowhead Files IND for RNAi Therapeutic ARC-520 to Begin Phase 2b Multiple-Dose Studies in Chronic Hepatitis B Patients12 December 2014
Alnylam Introduces Pipeline Growth Strategy for RNAi Therapeutics in Three Strategic Therapeutic Areas, or “STArs”News Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports